November 2022 Edition

We are excited to announce that a new best practices learning collaborative is under development as a part of the Rise to Immunize™ (RIZE) campaign: the RIZE Pneumococcal Vaccination Best Practices Collaborative (or PVAX Collaborative for short). This initiative is being led by AMGA’s Population Health Initiatives team and is sponsored by Pfizer Inc.

The goal of the PVAX Collaborative is to mobilize participating groups to develop strategies and implement interventions—based on the 2022 ACIP guidelines—to improve pneumococcal vaccination rates in primary care and specialty clinical settings. Groups will focus efforts on adults 19–64 years old with underlying medical conditions or other risk factors who are at high risk for pneumococcal disease. Up to 10 member groups from RIZE will be invited to take part in the PVAX Collaborative, with onboarding and implementation beginning January 2023 and Collaborative work running through April 2024.

Our team is looking forward to disseminating the insights, best practices, and lessons learned from the PVAX Collaborative with the larger campaign in the coming months.

As always, if you have any questions, please don’t hesitate to contact RiseToImmunize@amga.org.

Best,
- The RIZE Team

Webinar Preview

"Year 1 Data Review & RIZE Awards"

During the November campaign webinar, the RIZE team will share data insights from the first year of the campaign and present the 2022 ‘RIZE to the Challenge’ awards. Our three award-winning groups have demonstrated high performance on the campaign measures over Year 1 and will join us to share their success stories. We will hear from:

- Jeni Obenrader, PharmD, CDCES, pharmacy manager of clinical interdisciplinary care team at Premier Medical Associates, P.C.
- Jason Maxwell, MD, medical director at HealthPartners
- Janet Appel, MSN, RN, CCM, director of population health at Sharp Rees-Stealy Medical Group, Inc.

Join us on Nov. 17 to learn more about the data insights and success stories from the first year of the campaign.
Upcoming Dates

**Nov. 17** – Monthly campaign webinar: “Year 1 Data Review & RIZE Awards” at 2 p.m. ET (Register)

**Dec.** – No webinar. Happy holidays!

**Jan. 19** – Monthly campaign webinar: “Operationalizing CDC’s Adult Immunization Schedule” at 2 p.m. ET (Register)

Campaign Spotlight

This month we spotlight the National Foundation for Infectious Diseases’ (NFID’s) Annual Influenza/Pneumococcal Disease News Conference. On Oct. 4, leading national infectious disease experts shared data, trends, and insights on influenza and pneumococcal diseases and vaccinations. Information included final influenza vaccine coverage data from the 2021–2022 U.S. flu season, the importance of vaccination against flu and pneumococcal disease, results from a new NFID national survey of U.S. adults on vaccination attitudes and behaviors, and warnings of a possible severe flu season this year. Read more about and view the news conference on NFID’s website.

Resource of the Month

Together with our advisors and national experts, we have developed a value set of ICD-10 codes to help groups identify patients ages 19-64 with underlying medical conditions or other risk factors requiring a pneumococcal vaccination. Although the RIZE pneumococcal measure focuses on adults ages 66+, your organization is undoubtedly working to identify and vaccinate this additional patient population that is at increased risk for pneumococcal disease. We hope you find this additional resource valuable as you work to better protect your patients from vaccine-preventable diseases.